POS-347 PREVALENCE OF POLYCYSTIC KIDNEY DISEASE IN THE MID WEST OF IRELAND AND CANDIDACY FOR TOLVAPTAN THERAPY

• DOI: 10.1016/j.ekir.2021.03.363
• Publication Date: 2021-04-16T14:44:17Z
• Authors: J.W. TEH; B.W.T. Soh; L. Selvarajah; D. Moore; B. Moloney; P. O'Hara; L. Casserly
• Keywords: Tolvaptan; Candidacy

Tolvaptan is a vasopressin V2-receptor antagonist that inhibits cyst growth and slows the decline of kidney function in polycystic disease (PCKD). TEMPO 3:4 REPRISE Trials showed tolvaptan renal increase size. We aim to study prevalence Mid-West region Ireland their candidacy for therapy.